# Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

> clinical trial · VERIFIED · 2026-07-08

Status: ACTIVE_NOT_RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Breast Cancer

- Company: Novartis Pharmaceuticals
- Sector: Breast Cancer
- Primary source: https://clinicaltrials.gov/study/NCT05038735

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.